Symbols / APRE
APRE Chart
About
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.59M |
| Enterprise Value | -7.94M | Income | -13.04M | Sales | 488.24K |
| Book/sh | 1.82 | Cash/sh | 2.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.88 | PEG | — |
| P/S | 11.46 | P/B | 0.44 | P/C | — |
| EV/EBITDA | 0.58 | EV/Sales | -16.27 | Quick Ratio | 5.12 |
| Current Ratio | 5.20 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.12 | EPS next Y | -0.91 | EPS Growth | — |
| Revenue Growth | -99.50% | Earnings | 2025-11-12 08:00 | ROA | -41.90% |
| ROE | -74.72% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -1686.90% | Profit Margin | 0.00% | Shs Outstand | 6.99M |
| Shs Float | 4.71M | Short Float | 4.10% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 2.91 | 52W Low | 0.55 |
| Beta | 1.61 | Avg Volume | 2.16M | Volume | 115.47K |
| Target Price | $5.33 | Recom | Strong_buy | Prev Close | $0.81 |
| Price | $0.80 | Change | -1.85% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.33
Mean price target
2. Current target
$0.80
Latest analyst target
3. DCF / Fair value
$-23.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.80
Low
$4.00
High
$7.00
Mean
$5.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | main | Wedbush | Outperform → Outperform | $7 |
| 2026-01-29 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-12-18 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-08-13 | reit | Wedbush | Outperform → Outperform | $11 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-03-27 | main | Wedbush | Outperform → Outperform | $11 |
| 2024-03-26 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-03-10 | init | Maxim Group | — → Buy | $16 |
- $APRE stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 14
- Experimental cancer drug shrinks endometrial tumor by 50% in early trial - Stock Titan Wed, 18 Feb 2026 13
- Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga Wed, 18 Feb 2026 19
- Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits Wed, 18 Feb 2026 20
- Aprea Therapeutics stock falls after early-stage cancer drug data - Investing.com hu, 29 Jan 2026 08
- Aprea Therapeutics (APRE): Analyst Maintains Rating, Lowers Pric - GuruFocus ue, 10 Feb 2026 08
- New Strong Sell Stocks for Jan. 14 - Yahoo Finance Wed, 14 Jan 2026 08
- Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st Wed, 03 Dec 2025 08
- Aprea Highlights Encouraging Phase 1 Data for APR-1051 - TipRanks Wed, 18 Feb 2026 14
- $APRE stock is down 25% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- 12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga Fri, 20 Feb 2026 12
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga hu, 19 Feb 2026 12
- Insider Purchase: Director at $APRE Buys 21,459 Shares - Quiver Quantitative hu, 11 Dec 2025 08
- 12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga Wed, 18 Feb 2026 21
- Aprea Therapeutics Announces $5.6 Million Private Placement to Support Clinical Development of APR-1051 - Quiver Quantitative hu, 29 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28100 | 25009 | — | Purchase at price 0.89 per share. | GILAD OREN PH.D. | Chief Executive Officer | — | 2026-01-30 00:00:00 | D |
| 1 | 5700 | 5073 | — | Purchase at price 0.89 per share. | HAMILL JOHN P | Chief Financial Officer | — | 2026-01-30 00:00:00 | D |
| 2 | 21459 | 19575 | — | Purchase at price 0.91 per share. | DUEY MARC | Director | — | 2025-12-10 00:00:00 | D |
| 3 | 5000 | 4561 | — | Purchase at price 0.91 per share. | HAMILL JOHN P | Chief Financial Officer | — | 2025-12-10 00:00:00 | D |
| 4 | 1045 | — | — | Stock Award(Grant) at price 0.00 per share. | GRUIA GABRIELA | Director | — | 2025-06-05 00:00:00 | D |
| 5 | 1045 | — | — | Stock Award(Grant) at price 0.00 per share. | DUEY MARC | Director | — | 2025-06-05 00:00:00 | D |
| 6 | 1045 | — | — | Stock Award(Grant) at price 0.00 per share. | PAMAKCU RIFAT | Director | — | 2025-06-05 00:00:00 | D |
| 7 | 1045 | — | — | Stock Award(Grant) at price 0.00 per share. | HENNEMAN JOHN BELL III | Director | — | 2025-06-05 00:00:00 | D |
| 8 | 1045 | — | — | Stock Award(Grant) at price 0.00 per share. | BIZZARI JEAN-PIERRE | Director | — | 2025-06-05 00:00:00 | D |
| 9 | 1045 | — | — | Stock Award(Grant) at price 0.00 per share. | PETERS RICHARD | Director | — | 2025-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.37M | -15.43M | 38.55M | -37.49M |
| TotalUnusualItems | 71.80K | -38.93K | -75.74M | 317.40K |
| TotalUnusualItemsExcludingGoodwill | 71.80K | -38.93K | -75.74M | 317.40K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.96M | -14.29M | -112.66M | -37.13M |
| ReconciledDepreciation | 22.32K | 7.05K | 186.44K | 271.68K |
| EBITDA | -14.30M | -15.46M | -37.19M | -37.17M |
| EBIT | -14.32M | -15.47M | -37.37M | -37.45M |
| NetInterestIncome | 1.29M | 1.22M | 448.67K | 1.65K |
| InterestIncome | 1.29M | 1.22M | 448.67K | 1.65K |
| NormalizedIncome | -13.03M | -14.25M | -36.92M | -37.44M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.96M | -14.29M | -112.66M | -37.13M |
| TotalExpenses | 14.32M | 15.47M | 37.37M | 37.45M |
| TotalOperatingIncomeAsReported | -14.32M | -15.47M | -113.39M | -37.45M |
| DilutedAverageShares | 5.51M | 3.62M | 1.66M | 1.06M |
| BasicAverageShares | 5.51M | 3.62M | 1.66M | 1.06M |
| DilutedEPS | -2.35 | -3.95 | -67.99 | -34.80 |
| BasicEPS | -2.35 | -3.95 | -67.99 | -34.80 |
| DilutedNIAvailtoComStockholders | -12.96M | -14.29M | -112.66M | -37.13M |
| NetIncomeCommonStockholders | -12.96M | -14.29M | -112.66M | -37.13M |
| NetIncome | -12.96M | -14.29M | -112.66M | -37.13M |
| NetIncomeIncludingNoncontrollingInterests | -12.96M | -14.29M | -112.66M | -37.13M |
| NetIncomeContinuousOperations | -12.96M | -14.29M | -112.66M | -37.13M |
| PretaxIncome | -12.96M | -14.29M | -112.66M | -37.13M |
| OtherIncomeExpense | 71.80K | -38.93K | -75.74M | 317.40K |
| SpecialIncomeCharges | 0.00 | -76.02M | 0.00 | |
| OtherSpecialCharges | 76.02M | |||
| GainOnSaleOfSecurity | 71.80K | -38.93K | 281.53K | 317.40K |
| NetNonOperatingInterestIncomeExpense | 1.29M | 1.22M | 448.67K | 1.65K |
| TotalOtherFinanceCost | -448.67K | -1.65K | ||
| InterestIncomeNonOperating | 1.29M | 1.22M | 448.67K | 1.65K |
| OperatingIncome | -14.32M | -15.47M | -37.37M | -37.45M |
| OperatingExpense | 14.32M | 15.47M | 37.37M | 37.45M |
| OtherOperatingExpenses | -1.50M | -583.23K | ||
| ResearchAndDevelopment | 9.36M | 7.63M | 16.40M | 23.90M |
| SellingGeneralAndAdministration | 6.46M | 8.43M | 20.97M | 13.55M |
| GeneralAndAdministrativeExpense | 6.46M | 8.43M | 20.97M | 13.55M |
| OtherGandA | 6.46M | 8.43M | 20.97M | 13.55M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.48M | 3.74M | 2.66M | 1.09M |
| ShareIssued | 5.48M | 3.74M | 2.66M | 1.09M |
| TotalDebt | 0.00 | 190.47K | ||
| TangibleBookValue | 19.31M | 16.95M | 25.64M | 49.51M |
| InvestedCapital | 19.31M | 16.95M | 25.64M | 49.51M |
| WorkingCapital | 20.22M | 18.14M | 26.95M | 49.27M |
| NetTangibleAssets | 19.31M | 16.95M | 25.64M | 49.51M |
| CapitalLeaseObligations | 0.00 | 190.47K | ||
| CommonStockEquity | 19.31M | 16.95M | 25.64M | 49.51M |
| TotalCapitalization | 19.31M | 16.95M | 25.64M | 49.51M |
| TotalEquityGrossMinorityInterest | 19.31M | 16.95M | 25.64M | 49.51M |
| StockholdersEquity | 19.31M | 16.95M | 25.64M | 49.51M |
| GainsLossesNotAffectingRetainedEarnings | -10.63M | -10.61M | -10.62M | -10.36M |
| OtherEquityAdjustments | -10.63M | -10.61M | -10.62M | -10.36M |
| RetainedEarnings | -321.04M | -308.08M | -293.80M | -181.13M |
| AdditionalPaidInCapital | 350.97M | 335.64M | 330.06M | 241.00M |
| CapitalStock | 5.48K | 3.74K | 2.65K | 1.09K |
| CommonStock | 5.48K | 3.74K | 2.65K | 1.09K |
| TotalLiabilitiesNetMinorityInterest | 4.67M | 5.70M | 4.51M | 7.32M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.31M | 1.31M | 1.31M | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 1.31M | 1.31M | 1.31M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 0.00 | ||
| LongTermCapitalLeaseObligation | 0.00 | 0.00 | ||
| CurrentLiabilities | 3.36M | 4.39M | 3.20M | 7.32M |
| CurrentDeferredLiabilities | 0.00 | 528.97K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 528.97K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 190.47K | |||
| CurrentCapitalLeaseObligation | 0.00 | 190.47K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 465.01K | 1.02M | 1.40M | 1.42M |
| PayablesAndAccruedExpenses | 2.90M | 2.84M | 1.80M | 5.71M |
| CurrentAccruedExpenses | 1.54M | 1.17M | 960.36K | 3.93M |
| Payables | 1.35M | 1.67M | 842.75K | 1.77M |
| AccountsPayable | 1.35M | 1.67M | 842.75K | 1.77M |
| TotalAssets | 23.98M | 22.65M | 30.16M | 56.82M |
| TotalNonCurrentAssets | 403.35K | 129.08K | 2.32K | 239.05K |
| OtherNonCurrentAssets | 321.83K | 40.72K | 29.37K | |
| NetPPE | 81.52K | 88.36K | 2.32K | 209.68K |
| AccumulatedDepreciation | -72.44K | -50.12K | -43.07K | -117.01K |
| GrossPPE | 153.96K | 138.48K | 45.39K | 326.69K |
| OtherProperties | 148.70K | 133.23K | 40.13K | 276.58K |
| MachineryFurnitureEquipment | 5.26K | 5.26K | 5.26K | 50.11K |
| CurrentAssets | 23.58M | 22.52M | 30.15M | 56.58M |
| OtherCurrentAssets | 726.25K | 914.27K | 1.37M | 3.51M |
| PrepaidAssets | 3.51M | |||
| CashCashEquivalentsAndShortTermInvestments | 22.85M | 21.61M | 28.79M | 53.08M |
| CashAndCashEquivalents | 22.85M | 21.61M | 28.79M | 53.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.57M | -12.27M | -25.01M | -37.69M |
| IssuanceOfCapitalStock | 16.14M | 5.79M | 682.97K | 1.54M |
| CapitalExpenditure | -15.48K | -93.09K | ||
| EndCashPosition | 22.89M | 21.65M | 28.79M | 53.08M |
| BeginningCashPosition | 21.65M | 28.79M | 53.08M | 89.02M |
| EffectOfExchangeRateChanges | -7.18K | -8.40K | 38.76K | -2.47K |
| ChangesInCash | 1.25M | -7.13M | -24.33M | -35.94M |
| FinancingCashFlow | 14.82M | 5.14M | 682.97K | 1.75M |
| CashFlowFromContinuingFinancingActivities | 14.82M | 5.14M | 682.97K | 1.75M |
| NetOtherFinancingCharges | -1.32M | -648.93K | ||
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 208.37K | |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 16.14M | 5.79M | 682.97K | 1.54M |
| CommonStockIssuance | 16.14M | 5.79M | 682.97K | 1.54M |
| InvestingCashFlow | -15.48K | -93.09K | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -15.48K | -93.09K | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -15.48K | -93.09K | 0.00 | 0.00 |
| PurchaseOfPPE | -15.48K | -93.09K | 0.00 | 0.00 |
| OperatingCashFlow | -13.56M | -12.18M | -25.01M | -37.69M |
| CashFlowFromContinuingOperatingActivities | -13.56M | -12.18M | -25.01M | -37.69M |
| ChangeInWorkingCapital | -1.06M | 1.62M | -1.76M | -8.33M |
| ChangeInOtherWorkingCapital | -528.97K | 528.97K | ||
| ChangeInOtherCurrentLiabilities | 0.00 | -186.70K | -268.73K | |
| ChangeInPayablesAndAccruedExpense | -429.75K | 637.74K | -3.76M | -7.95M |
| ChangeInAccruedExpense | -115.54K | -189.72K | -2.90M | -5.22M |
| ChangeInPayable | -314.21K | 827.46K | -858.51K | -2.73M |
| ChangeInAccountPayable | -314.21K | 827.46K | -858.51K | -2.73M |
| ChangeInPrepaidAssets | -96.67K | 451.99K | 2.19M | -109.34K |
| OtherNonCashItems | 17.43K | 72.52M | ||
| StockBasedCompensation | 489.44K | 444.46K | 16.98M | 7.81M |
| DepreciationAmortizationDepletion | 22.32K | 7.05K | 186.44K | 271.68K |
| DepreciationAndAmortization | 22.32K | 7.05K | 186.44K | 271.68K |
| Depreciation | 7.05K | 186.44K | 271.68K | |
| OperatingGainsLosses | -71.80K | 38.93K | -281.53K | -317.40K |
| NetForeignCurrencyExchangeGainLoss | -71.80K | 38.93K | -281.53K | -317.40K |
| NetIncomeFromContinuingOperations | -12.96M | -14.29M | -112.66M | -37.13M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for APRE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|